The FDA has accepted Ascendis Pharma's supplemental Biologics License Application for TransCon hGH in adult growth hormone deficiency, marking a significant step toward expanding its market and ...

TransCon CNP matches BioMarin's Voxzogo for achondroplasia with plans for regulatory filings in 2025, showing potential for ...

At the heart of the agreement is an exclusive worldwide license to Copenhagen-based Ascendis' TransCon technology ... a long-acting growth hormone for children with growth hormone deficiency.

“Our expanding TransCon technology platform and partnerships ... in an estimated 6.5% market share of the total U.S. growth hormone market for 2024 (based on third party prescription data).

“Ascendis is well-positioned for rapid revenue growth with ... First planned TransCon protein degrader product candidate designed to normalize excess FGF-23 hormone levels for patients with ...

“Our expanding TransCon technology platform and partnerships ... BLA for SKYTROFA for the treatment of adults with growth hormone deficiency and Ascendis’ plans for a U.S. commercial launch ...